Sustainability update

For investors and analysts

6 July 2026

Cautionary statements regarding forward-looking statements

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter 'the Group') provides the following cautionary statement:

This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group's control, include, among other things: the risk of failure or delay in delivery of pipeline or launch of new medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group's commercial strategies; the risk of pricing, affordability, access and competitive pressures; the risk of failure to maintain supply of compliant, quality medicines; the risk of illegal trade in the Group's medicines; the risk of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data and artificial intelligence in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet our sustainability targets, regulatory requirements or stakeholder expectations with respect to the environment; the risk of failure to meet regulatory and ethical expectations on commercial practices, including anti-bribery anti-corruption, anti-fraud and scientific exchanges; the risk of the safety and efficacy of marketed medicines being questioned; the risk of adverse outcome of litigation and/or governmental investigations; intellectual property risks related to the Group's products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of geopolitical and/or macroeconomic volatility disrupting the operation of our global business; the risk of failure in internal control, financial reporting or the occurrence of fraud; and the risk of unexpected deterioration in the Group's financial position.

AstraZeneca

Pam Cheng

Executive Vice President,
Global Operations, IT &
Chief Sustainability Officer

Our changing world requires concerted action for a healthier future

The climate crisis is worsening the burden of disease

Health systems are unable to cope with rising demands

Health disparities are widening within and between countries

Transformative technologies to drive 2030+ growth

Weight management and risk factors	Antibody drug conjugates and radioconjugates	Next-generation immuno-oncology bispecifics	Cell therapy and T-cell engagers	Gene therapy and gene editing
Establish and lead in new paradigm for weight management	Replace systemic chemotherapy and radiotherapy	Replace existing PD-1/ PD-L1 inhibitors	Develop scalable therapies to address multiple diseases	Make cure possible for a range of rare diseases

Artificial Intelligence is accelerating all aspects of innovation and execution

Our Sustainability strategy

Sustainability impact:
Through the power of science and innovation, we are taking action on **climate and nature**, **health equity** and **health systems resilience**.

How we do business:
We are guided by our Values and invest in our people to create long-term value, resilience and trust by operating responsibly, ethically and with robust governance.

Delivering for patients sustainably

Climate and Nature

88%

Reduction in Scope 1 & 2 greenhouse gas emissions vs 2015



>80%

Supplier spend with companies committed to science-based targets

1st

Inhaled respiratory medicine approved using next-generation propellant



81%

Global vehicle fleet are battery electric vehicles



23%

Reduction in water withdrawal and waste vs 2015

Delivering for patients sustainably

Health Equity



>40%

of our genomics data comes from under-represented populations

>60

partnerships with NGOs through our Young Health Programme

49m+

people reached with health education, screening and early detection since 2024



156m

people in underserved communities positively impacted since 2024

Delivering for patients sustainably

Health Systems Resilience

37

countries with Partnership for Health System Sustainability & Resilience (PHSSR) projects

>30

reports launched with policy recommendations on how to act early on NCDs and strengthen health systems

>200

policymakers engaged on health systems strengthening and collaboration opportunities

Our Sustainability targets to 2030

Climate and nature

- **35%** reduction in Scope 3 emissions*
- **>100m** trees planted through AZ Forest
- **3x** energy productivity
- **50%** waste circularity rate
- **Water stewardship strategies** delivered at key sites

Health equity

- **1 billion** people positively impacted, including 400 million from underserved groups

Health systems resilience

- **45 countries** with health systems strengthened through partnerships with governments and evidence-based advocacy

*vs 2019 baseline. Scope 1 & 2 target: By 2026 reduce greenhouse gas (GHG) emissions by 98% vs 2015

2030 target

35% reduction in Scope 3 emissions

vs 2015 baseline







Transitioning to next-generation propellant (NGP) for inhaled medicines, with near-zero global warming potential

~25%[1]

Pressurised metered dose inhalers (pMDI)

Transition timeline

First industry-wide approval	Positive EU CHMP opinion	Transition progress (*Breztri* / *Trixeo* *)	Broad portfolio transition
Pressurised metered dose inhaler (pMDI) with NGP approved for use in UK	Endorsed for use in the EU	**Transition complete:** UK, France, Spain, Portugal, Germany. Other European countries underway **Approvals:** Australia, New Zealand **Regulatory Submissions:** US, China, Japan	On track to transition broad portfolio of inhaled medicines
May 2025	July 2025	July 2026	June 2030

1. Based on 2025 data

2. *Breztri* and *Trixeo* are different brand names for the same medicine. The name *Breztri* is used in the US, China and Japan, *Trixeo* is used in Europe

2030 target

1 billion people positively impacted

including **400 million from underserved groups**

Determinants of health outcomes



Early detection



Precision diagnostics

Guideline-based care

Treatment adherence and disease monitoring

Our Health Equity strategy

We aim to deliver health equity impact across key focus areas to close healthcare gaps among underserved patients, so that more people can benefit from innovative medicines.



Science

- Ensuring more individuals **can equitably benefit** from our trials, science and capabilities
  - Genomics
  - Clinical trial representation
  - Open innovation

Healthcare delivery

- Improving **equitable health outcomes,** focusing on early detection, precision diagnosis and guideline-concordant treatment
  - Lung health programmes
  - Rare diseases
  - Healthy Heart Africa

Community investment

- Addressing the **root causes of health inequities** by investing in underserved communities, via
  - Young Health Programme
  - Disaster relief
  - Product donations
  - STEM

Underpinned by capabilities and engagement to build trust with partners and purpose with employees

Sustainability is a core part of our business strategy

Q&A

Pam Cheng
EXECUTIVE VICE PRESIDENT,
GLOBAL OPERATIONS,
IT & CHIEF SUSTAINABILITY OFFICER

Stefan Weber
VICE PRESIDENT, POLICY, ADVOCACY
AND HEALTH EQUITY

Liz Chatwin
VICE PRESIDENT,
GLOBAL SUSTAINABILITY AND SAFETY,
HEALTH & ENVIRONMENT

Philip Sparks
DIRECTOR, INVESTOR RELATIONS